- Home
- ITOC vs SXTP Comparison
ITOC vs SXTP Comparison
Compare ITOC & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | SXTP |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | China | United States |
| Employees | 7 | 3 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITOC | SXTP |
|---|---|---|
| Price | $0.33 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 152.3K | 61.4K |
| Earning Date | 03-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.34 |
| 52 Week High | $1.15 | $8.62 |
Technical Indicators
Market Signals| Indicator | ITOC | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 44.42 |
| Support Level | $0.28 | $1.29 |
| Resistance Level | $0.34 | $1.59 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 25.31 | 15.22 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.